




PHARMACEUTICAL 2023

Aprea Therapeutics Inc.
Rank 429 of 446





PHARMACEUTICAL 2023

Aprea Therapeutics Inc.
Rank 429 of 446

The relative strengths and weaknesses of Aprea Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aprea Therapeutics Inc. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 24% points. The greatest weakness of Aprea Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 477% points.

The company's Economic Capital Ratio, given in the ranking table, is -398%, being 441% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	30,154
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,201
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	-264
Other Expenses	76,020
Other Liabilities	0
Other Net Income	730
Other Revenues	0
Property and Equipment	2.3
Research and Development	16,402
Selling, General and Administrative Expense	20,970

Output Variable	Value in 1000 USD
Assets	30,156
Liabilities	3,201
Expenses	113,392
Revenues	0
Stockholders Equity	26,955
Net Income	-112,662
Comprehensive Net Income	-112,794
Economic Capital Ratio	-398%